Cardiovascular Risk Management

Heart disease is one of the leading causes of death for adults in America and is something many people live with for the rest of their lives. With this in mind, it is understandable to question if it can be reversed. After all, the ability to do so would dramatically improve lives while simultaneously improving...

The onset of cardiometabolic conditions, like diabetes, occurs in younger ages for Black and Hispanic women as compared to White women. A 2022 cohort study published in JAMA Network Open evaluated racial/ethnic disparities in age-of-onset for four cardiometabolic outcomes. The study also accounted for multiple forms of potential selection bias. The cardiometabolic outcomes examined were...

ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating ATTR-CM is, in most cases, significantly improved when it is discovered early, although this poses some unique challenges of its...

Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends to have high morbidity, poor treatment outcomes, and high treatment expenditure. Recent advances in therapeutic strategies for ATTR-CM have shown...

ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM is caused by transthyretin (TTR) amyloid protein build ups in the myocardium and other organs, in most cases the peripheral...

With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be included in the list of transplantation indications. Cardiomyopathy caused by transthyretin amyloidosis cardiomyopathy (ATTR-CM) is progressive and fatal. Patients with...

In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded transthyretin amyloid fibrils, resulting in end-organ dysfunction. ATTR-CM patients present with symptoms of invasive cardiomyopathy and heart failure necessitating expensive...

In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin amyloid cardiomyopathy (ATTR-CM). Treatment with dapagliflozin was found to be well-tolerated in patients with ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart disease that can be fatal. In recent years, more and more people have been diagnosed and subsequently hospitalized...

The awareness and diagnosis of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is challenging, despite ATTRwt being more common than previously thought. Screening is necessary for early detection and diagnosis of ATTRwt CM, as well as for timely treatment of the disease. The clinical characteristics of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) can vary among affected...